These results suggest that simvastatin may attenuate the pathological process of inflammatory bowel disease (IBD) by modulating the NF-κB signaling pathway and suppressing the expression of pro-inflammatory genes, indicating its potential as a therapeutic agent for IBD (61). The gene discussed is NFKB1; the disease is inflammatory bowel disease.